FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Evidence for efficacy is based on the results from the MIRASOL study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive Surgery in Patients with Breast Cancer Sentinel-Node Macrometastases
Findings from the SENOMAC study
A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year iDFS Among Patients with HER2-positive Early Breast Cancer
Findings from the PHERGain study
Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence In Trial-Fit Older Compared with Younger Patients with Stage III Colon Cancer
Findings from an ACCENT/IDEA pooled analysis of 12 adjuvant trials
EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate
New indication concerns combination with oxaliplatin, 5-FU and LV for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma
Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following Progression Despite Previous Anthracycline- or Ifosfamide-based Treatment
Findings from the SPEARHEAD-1 study
FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
Evidence for efficacy is based on the results from the PhALLCON study
PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for Patients with Resectable Oesophageal/Gastro-oesophageal Junction Cancers
Findings from a phase Ib study
EMA Recommends Extension of Therapeutic Indications for Enzalutamide
New indication concerns the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer
Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed, Previously Untreated, High-Risk, Locally Advanced Cervical Cancer
Findings from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor in the Adjuvant Treatment for HR-positive, HER2-negative EBC
Findings from a protocol-specified interim analysis of the NATALEE study
EMA Recommends Extension of Therapeutic Indications for Selpercatinib
New indication concerns the treatment of patients with advanced RET fusion-positive solid tumours